Descripción de la empresa
Milestone Pharmaceuticals Inc. operates as a biopharmaceutical entity dedicated to the research, development, and commercialization of therapeutic agents specifically targeting cardiovascular conditions within the United States and Canadian markets. The company functions within the broader healthcare sector and the specialized biotechnology industry, which involves high-risk, high-reward ventures focused on advancing medical treatments through scientific innovation and clinical trials. Its current scale is defined by a market capitalization of $189.44M, an annual revenue of $1.55M based on trailing twelve-month figures, and an operational workforce comprising 38 employees. These financial dimensions indicate that the company is a micro-cap biotechnology firm with a revenue base significantly smaller than its market valuation, suggesting that the market price largely reflects the potential value of its pipeline assets rather than current operational cash flows.
Salud financiera
The company reported revenue of $1.55M over the trailing twelve months, yet this modest income was accompanied by a net income of $-63.058M and an EBITDA of $-62.026M, revealing a substantial gap between top-line generation and bottom-line profitability. This significant disparity highlights a cost structure heavily weighted toward research and development expenditures, clinical trial costs, and operational overhead typical of early-stage biotech entities where expenses far outpace current sales. The free cash flow stands at $-28.90325M, indicating that the company is burning through cash reserves to fund its strategic initiatives and has limited financial flexibility without external capital raises. Regarding profitability metrics, the gross margin is reported at 100.0%, which suggests that the cost of goods sold for its products is negligible or fully offset by revenue, while the operating margin is -1116.2% and the profit margin is 0.0%, both figures pointing to deep operational losses relative to sales volume. The balance sheet shows $105.96M in cash and cash equivalents against $58.38M in debt, resulting in a debt-to-equity ratio of 139.76, which implies a highly leveraged position relative to shareholders' equity despite the absolute cash balance. However, the current ratio of 8.01 indicates a very strong short-term liquidity position, suggesting the company possesses ample current assets to cover its short-term liabilities. Furthermore, the return on equity is -229.7% and the return on assets is -41.1%, metrics that reflect the dilutive impact of negative earnings on shareholder value and the inefficient generation of income from the asset base in the current reporting period.
Evaluación de valoración
The trailing twelve-month P/E ratio is not available due to negative earnings, while the forward P/E is listed as -1.64, a figure that implies the market is pricing in future earnings recovery or is utilizing alternative valuation methodologies for a currently unprofitable entity. The price-to-book ratio stands at 4.72, indicating that the stock trades at a significant premium of approximately 372% over its book value, which is common for biotech companies where the market values the intangible pipeline assets higher than the tangible assets recorded on the balance sheet. Alternative valuation multiples such as the price-to-sales ratio of 122.54 and an EV/EBITDA of 0.34 suggest that the company is being valued primarily on its revenue potential rather than earnings, with the low EV/EBITDA reflecting the heavy cash burn and lack of current profitability. The stock has traded between a 52-week low of $0.63 and a 52-week high of $3.06, meaning the current price sits at the upper end of its recent trading range if near the high, or potentially below the high depending on the specific day, though the range defines the maximum volatility experienced in the last year. The beta of 0.69 indicates that the stock's price volatility is less than that of the broader market, suggesting it moves with lower sensitivity to general market fluctuations compared to large-cap equities.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of earnings velocity against sales expansion, but the absence of growth rates in the data reflects the early-stage nature of the business where historical growth metrics are not yet established. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that it retains all available earnings and cash flow to reinvest into research, development, and commercialization efforts rather than distributing income to shareholders. This reinvestment strategy is standard for biotechnology firms in the development phase, where capital allocation toward clinical trials and regulatory approvals takes precedence over shareholder distributions. Consequently, the overall growth and income profile is characterized by a complete focus on capital accumulation and asset building to achieve future commercialization milestones, with no current mechanism for generating passive income for investors.